The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY 12144, USA.
Am J Alzheimers Dis Other Demen. 2010 Aug;25(5):414-24. doi: 10.1177/1533317510372372. Epub 2010 Jul 2.
Alzheimer's disease (AD) is a devastating neurodegenerative disorder that currently affects millions of Americans. There is no cure at present and no real long-term hope for patients with AD. While partially effective in improving symptoms, currently available treatments approved by the US Food and Drug Administration (FDA) do not halt progression of AD, or address the underlying mechanism of the disease, in part because the etiology of AD is still an active area of investigation. Identification of risk factors and the pathogenic mechanism of AD hold the promise of bringing forth novel treatments and perhaps even a cure. In this review, we will summarize some of the risk factors for AD, AD diagnosis, and current treatments. Novel therapeutic strategies such as inhibition of beta-amyloid peptide (Abeta), tau-mediated pathogenesis, and receptors for advanced glycation end products (RAGE), as well as neuroprotective and anti-inflammatory approaches and the impact of cholesterol-lowering, botanical, and nutritional agents are also reviewed.
阿尔茨海默病（AD）是一种破坏性的神经退行性疾病，目前影响着数以百万计的美国人。目前尚无治愈方法，AD 患者也没有真正的长期希望。虽然部分有效改善症状，但目前美国食品和药物管理局（FDA）批准的可用治疗方法并不能阻止 AD 的进展，也不能解决疾病的根本机制，部分原因是 AD 的病因仍然是一个活跃的研究领域。确定 AD 的风险因素和发病机制有望带来新的治疗方法，甚至可能治愈。在这篇综述中，我们将总结 AD 的一些风险因素、AD 的诊断和当前的治疗方法。还回顾了新型治疗策略，如抑制β-淀粉样肽（Abeta）、tau 介导的发病机制和晚期糖基化终产物受体（RAGE），以及神经保护和抗炎方法，以及降低胆固醇、植物和营养剂的影响。
